HALO - Halozyme Therapeutics, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Halozyme Therapeutics Non-GAAP EPS of $0.82 misses by $0.01, revenue of $230.04M misses by $1.1M
• Halozyme Therapeutics Q4 2023 Earnings Preview
• J&J seeks expanded FDA approval of Darzalex Faspro for multiple myeloma
• EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze
• Lipocine licenses Tlando testosterone therapy to Verity Pharma
• Regeneron’s high-dose Eylea, argenx’s Vyvgart injectable among latest approvals in Japan
• Halozyme’s early 2023 results indicate a mixed performance
• Halozyme gains as U.S. and EU clear Enhanze-based products
• Top overweight stocks with high free cash flow and EPS growth - MS
• JNJ multiple myeloma therapy outperforms standard of care by 58%
• argenx slips as autoimmune disorder therapy fails in pivotal trial
• Teva gains U.S. approval for generic version of osteoporosis injection
• Argenx Vyvgart injectable granted EU nod for myasthenia gravis
• Halozyme Therapeutics Non-GAAP EPS of $0.75 beats by $0.04, revenue of $216M in-line
• Halozyme, Acumen enter collaboration for Alzheimer's drug candidate
• Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more
• Halozyme Therapeutics Q3 2023 Earnings Preview
• Bristol Myers succeeds in Phase 3 trial for subcutaneous Opdivo
• Roche granted U.K. approval for subcutaneous Tecentriq
• Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.10, revenue of $221.04M beats by $21.09M